American Century Companies’s Co-Diagnostics CODX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-380
Closed -$12.6K 2855
2023
Q2
$12.6K Sell
380
-6,993
-95% -$268K ﹤0.01% 2787
2023
Q1
$327K Buy
7,373
+276
+4% +$22.1K ﹤0.01% 2274
2022
Q4
$537K Buy
7,097
+885
+14% +$82.9K ﹤0.01% 2026
2022
Q3
$598K Buy
6,212
+2,798
+82% +$391K ﹤0.01% 1894
2022
Q2
$575K Buy
3,414
+776
+29% +$118K ﹤0.01% 1867
2022
Q1
$489K Buy
2,638
+508
+24% +$105K ﹤0.01% 1976
2021
Q4
$571K Buy
+2,130
New +$559K ﹤0.01% 1868

Other funds holding CODX

American Century Companies's CODX Position: Q3 2023 in Review

American Century Companies sold out of Co-Diagnostics (CODX) in Q3 2023, closing a stake of 380 shares — an estimated $12.6K sold.

American Century Companies first reported a position in CODX in Q4 2021 and held it in 7 quarters. The position peaked at $598K in Q3 2022. 43 funds tracked by Wall St. Rank hold CODX as of Q3 2023.

  • American Century Companies reported no remaining Co-Diagnostics position as of Q3 2023 after selling out during the quarter.
  • American Century Companies sold 380 Co-Diagnostics shares in Q3 2023, an estimated $12.6K.
  • American Century Companies first reported a position in Co-Diagnostics in Q4 2021 and held it in 7 quarters.
  • American Century Companies's Co-Diagnostics position peaked at $598K in Q3 2022.
  • 43 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2023.

Based on American Century Companies's 13F filing for Q3 2023, filed 13 Nov 2023.